It is known that men of African descent are more likely to get prostate cancer and die from prostate cancer compared to their non-Hispanic white counterparts. The incidence of and mortality from prostate cancer in Hispanic and Latino men is increasing, while Asian men continue to be less affected by the disease than other races and ethnicites. Despite these differences, prostate cancer clinical trials (and clinical trials in general) tend to over-enroll non-Hispanic white patients. We surveyed 72 phase III and phase IV prostate cancer clinical trials and found that 83.4% of men in treatment trials, 84.6% of men in prevention trials, and 97.5% of men in screening trials were non-Hispanic white. Race and ethnicity of participants is often not reported in clinical trial results, and if the data is reported, it’s done inconsistently. Globally, only 2 out of the 67 countries in Africa and the Caribbean were included in the analyzed trials. Read the manuscript, associated press release, and media interviews below calling for diversifying clinical trials, particularly through supporting clinical trial infrastructure at underrepresented medical centers in the US and abroad:
